Top 5 Stocks to Buy Now Before 2027 (High Growth Stocks)

Ask most people where the growth is heading into 2027 and they'll point you to the same handful of trillion dollar names everyone already owns.

A note from our sponsors...

10 AI Infrastructure Stocks to Watch

Free report reveals 10 publicly traded companies positioned across key layers of the AI ecosystem, from chip fabrication and custom silicon to data storage, connectivity, and cooling solutions. Plus insight into the major risks that could impact the AI infrastructure trade, including valuation concerns, industry cycles, geopolitical challenges, and execution risks.

Get your FREE copy here.

A few of those popular names might actually be worth the hype, and one of them makes this list. But the rest are not the names you'd think of. They're companies the quant system is quietly flagging, growing their earnings fast, with solid overall fundamentals, while barely anyone's watching.

Every single one earns the highest rating the system gives. And a few of them have already started to move, which is not a reason to stay away. It's often the opposite.

Note: These picks are also available in our recent YouTube video … Check it out here. 

Ooma (OOMA)

We'll start with a name that doesn't get attention or headlines, Ooma (OOMA).

They sell cloud communications for businesses, phone systems, connectivity, the plumbing that lets a company of any size run its calls and its offices through the internet. Boring on the surface. The numbers underneath are anything but. The stock has had a nice run, but there's still enough juice left in the tank for more.

Ooma's earnings are forecast to grow nearly 60% a year, several times what the rest of the telecom space is expected to do. That's the engine here. And revenue growth is also expected to outpace the industry.

Ooma has come in ahead of EPS estimates for 12 quarters in a row now, with some very nice year over year growth, a steady streak that tells you management knows how to set a bar and clear it.

Wall Street coverage is thin. Only a few analysts follow Ooma at all. But all 3 analysts who track the stock give it a Strong Buy recommendation.

So what does the system see? Ooma earns an A, a Strong Buy recommendation, and it lands in the top 1% of every stock tracked. The Zen Ratings break every company into component grades, each one a ranking against the whole market.

Sentiment comes in at the top 14%, that's the smart money starting to lean in. Momentum, the top 19%. And the standout, Growth, the top 1% of the entire market.

If this small, overlooked grower is one way to play this, the next name shows you what happens when a company that Wall Street does love is still trading like a bargain.

Jazz Pharmaceuticals (JAZZ)

Next up is Jazz Pharmaceuticals (JAZZ), a stock up almost 90% on the 1-year chart, so not an underappreciated name. There's still a case for why it can go even further.

Jazz is a specialty drug maker with two engines. A durable, cash generating franchise in sleep disorders, and a fast growing arm in cancer treatment. That oncology push is the part to watch. Its newer cancer therapies are expanding into more uses, and that's the piece analysts expect to drive the next leg of growth.

Names like this are exactly what get dug into on the free live training every Monday, more on that a little later.

Here's the hook. Jazz is growing, analysts forecast earnings growth of nearly 24% a year, twice as fast as the broader biotech industry, and yet the stock trades at a growth adjusted price that looks genuinely cheap.

Its PEG ratio sits at 0.68. PEG is the price to earnings ratio divided by the growth rate, and anything under 1 means you're not overpaying for that growth. Under 0.7 on a company growing like this is the kind of number that makes you look twice.

And Wall Street is pounding the table here. Seventeen analysts cover Jazz, and they land on a consensus Strong Buy recommendation. Better still, all of the most bullish coverage comes from analysts that rank in the very top on Wall Street for stock picking, exactly what you want to see.

The system agrees. Jazz earns an A, a Strong Buy recommendation, with the overall fundamentals scoring in the top 4% of every stock tracked. Momentum comes in at the top 14%. Financials, the top 24%, still solid operational quality. And the standout, Value, the top 1% of the entire market. That is a rare thing, a company this profitable, this fast growing, after that monster surge mentioned above, and it still lands in the top 1% for value.

The real weak spot is Sentiment, a D grade, all the way down in the bottom 17% of the market. The smart money crowd clearly hasn't committed here yet. But top 1% value, a Strong Buy recommendation from the sharpest analysts on the Street, and earnings compounding at 24% a year, a company growing this fast at a price this reasonable is something worth a closer look.

Astronics (ATRO)

Moving on to Astronics (ATRO).

They build the electrical power systems, lighting, and avionics that go inside aircraft, commercial jets, military planes, and the test gear that certifies all of it before it leaves the hangar. If a plane needs to move power around cleanly, there's a good chance Astronics is somewhere in it.

Astronics blew past estimates in Q2, and has now beaten EPS forecasts for 4 quarters in a row. On top of that, management raised its guidance for the full year, and fresh orders have been rolling in, including new defense and next generation aircraft work. This is a company where the order book is filling up faster than Wall Street expected.

Fair warning, this stock has already run. Shares are up more than 100% over the past year. But here's why the move may not be over. The stock still isn't expensive relative to growth prospects, the PEG ratio sits at roughly 1.1, and for reference, the average stock's PEG is closer to 1.5.

On the analyst side, coverage is thin but pointed. The 1 analyst covering it closely, from TD Cowen, ranks in the top 12% of the whole Street for stock picking, and carries a Strong Buy recommendation, with a price target that implies an upside of more than 30% from here. Thin coverage on a name growing like this means the rest of the Street simply hasn't shown up yet.

And the data loves it. Astronics earns an A, a Strong Buy recommendation, in the top 1% of every stock tracked. Sentiment comes in at the top 14%. Financials, the top 7%. And the standout, Growth, the top 1% of the entire market. Momentum and Safety both grade above the pack too.

The one thing to keep an eye on is the balance sheet, Astronics carries more debt than ideal, a leftover from those lean recovery years. That's the honest tradeoff here.

But the read here is a company firing on real fundamental strength, with the market moving in behind it. You've got a raised outlook, fresh government orders, top tier analyst conviction, and a top 1% rating.

The Zen Ratings are updated daily, so be sure to visit the quote pages on wallstreetzen.com to see the latest ratings for this or any other stock.

Micron Technology (MU)

This next one is the name almost everyone knows, and it earns its spot here.

The stock is Micron (MU). Micron is the only American maker of memory chips, the high bandwidth memory that every modern AI processor needs to actually function. Right now, that memory is the real bottleneck in the whole AI buildout.

Demand has run so far ahead of supply that Micron has effectively sold out its high bandwidth memory for the year ahead, price and volume already locked in. That's not a company chasing orders, it's a company rationing what it can make.

Micron's earnings are forecast to grow nearly 42% a year, faster than the industry and faster than the market.

Now the elephant in the room. Micron has been a rocket, up enormously over the past year. But it's actually pulled back since a peak of around $1,250 in late June to below $1,000 per share. Relative to growth, the stock has an attractive valuation, with the PEG at 0.51x.

And on top of all that, Wall Street is all in on Micron. 26 analysts cover Micron, and they land on a consensus Strong Buy recommendation, 17 of them rating it a Strong Buy, zero at Sell. The average price target implies an upside of more than 45%, and the most bullish analysts on the panel, a lot of whom rank at the very top, have price targets that imply more than 100% upside.

The system puts it near the very top. Micron earns an A, a Strong Buy recommendation, in the top 1% of every stock tracked. Value comes in at the top 8%, yes, a stock this hot still grading well on value. Momentum, the top 5%. And the two standouts, Growth and Financials, both in the top 2% of the entire market.

The honest risk with Micron is the one it's always carried, memory is cyclical. Prices boom and they bust, and when the cycle eventually cools, a name like this feels it. That's the trade off with the fastest part of the chip market. But sold out supply, top 1% growth and financials, and a recent pullback that hands you a better entry, Micron is a case where the most obvious answer happens to be the right one.

Before the last stock, one quick thing. If you want to stay one step ahead of the market, join the Live training every Monday. That is when we share the updated market outlook and trading plan to outperform, plus the Trade of the Week based on our proven Zen Ratings quant model.

It's a free event, but you do need to register. Just go to wallstreetzen.com/live.

Eton Pharmaceuticals (ETON)

Time for the final pick on the list. The single fastest grower on this entire list, and it's a name that's easy to have missed, despite a monster rally.

The company is Eton Pharmaceuticals (ETON), and they develop and sell treatments for rare diseases. That's the whole model, find serious conditions that affect small patient populations, and become the one company that serves them. It's a niche the giants ignore, but one where you can command real pricing and face very little competition.

Eton just reported in August and crushed the number, earnings came in more than double what Wall Street expected. The portfolio is scaling, new products are launching, and the growth has gone nearly vertical.

Analysts forecast earnings growth north of 90% a year, that's almost 5 times faster than the rest of the pharma space. Revenue is forecast to grow more than 40% per year, roughly 4 times as fast as the industry average.

Now, the chart. This one has already run. Shares are up more than 200% over the past year, sitting right near an all time high. And a stock that's moved like that can swing hard, that's just the nature of a small, fast grower. But a run like that is often a company being discovered, not a company that's finished.

Coverage is still thin, only 4 analysts follow Eton so far, but the stock has 2 Strong Buy recommendations and 2 Buy recommendations, so the outlook is unanimously bullish. The price targets on the board aren't all that impressive, but the fundamentals are.

Eton earns an A, a Strong Buy recommendation, in the top 1% of every stock tracked. There's a really well rounded cluster of strength here, all near the very top. Financials come in at the top 5%, and so does Growth. The two standouts are Momentum, in the top 3%, and Sentiment, in the top 6%, the smart money moving in. Different facets, all saying the same thing, a business accelerating, and the market rewarding it in real time.

Here's the honest risk. Eton is small, and it trades like it. After a move this big, the swings can be sharp, so this is the volatile end of the market and you'd want to size it accordingly. But with the fastest earnings growth on the list, a fresh quarter that doubled expectations, and the highest rating the system gives, Eton is the one on this list worth watching closest of all.

Conclusion

So there's the growth playbook heading into 2027. Every one of them earns a Strong Buy recommendation today, but remember, these grades update daily, and fast movers can move fast in both directions, so if any of them caught your eye, it pays to look sooner rather than later.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.